In our study, patients with T2DM diagnosed with cervical cancer within 6 months of SGLT2 inhibitor use were excluded to ensure a clear temporal relationship between SGLT2 inhibitor use and the occurrence of cervical cancer. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.